ABVX Abivax S.A.

Nasdaq www.abivax.com


$ 97.58 $ 0.00 (0 %)    

Wednesday, 15-Oct-2025 07:19:28 EDT
QQQ $ 603.09 $ 0.00 (0 %)
DIA $ 465.17 $ 0.00 (0 %)
SPY $ 666.57 $ 0.00 (0 %)
TLT $ 90.94 $ 0.00 (0 %)
GLD $ 386.17 $ 0.00 (0 %)
$ 97.82
$ 95.99
$ 97.46 x 100
$ 98.06 x 100
-- - --
$ 4.77 - $ 98.39
1,007,718
na
6.17B
$ 1.05
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 barclays-initiates-coverage-on-abivax-with-overweight-rating-announces-price-target-of-142

Barclays analyst Etzer Darout initiates coverage on Abivax (NASDAQ:ABVX) with a Overweight rating and announces Price Target...

 guggenheim-maintains-buy-on-abivax-raises-price-target-to-150

Guggenheim analyst Yatin Suneja maintains Abivax (NASDAQ:ABVX) with a Buy and raises the price target from $101 to $150.

 btig-maintains-buy-on-abivax-raises-price-target-to-120

BTIG analyst Julian Harrison maintains Abivax (NASDAQ:ABVX) with a Buy and raises the price target from $112 to $120.

 why-is-abivax-stock-trading-higher-on-monday

Abivax said Phase 3 trials showed obefazimod improved clinical outcomes in ulcerative colitis, meeting key endpoints with no ne...

Core News & Articles

Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused o...

 reported-sunday-abivax-announces-late-breaking-phase-3-data-showing-obefazimod-achieved-164-placebo-adjusted-remission-rate-at-week-8-in-ulcerative-colitis

50 mg once-daily dose of obefazimod led to a pooled 16.4% (p<0.0001) placebo-adjusted clinical remission rate at Week 8; met...

Core News & Articles

Late Breaking Abstract titled EFFICACY AND SAFETY OF OBEFAZIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLIT...

 jmp-securities-maintains-market-outperform-on-abivax-raises-price-target-to-114

JMP Securities analyst Jason N. Butler maintains Abivax (NASDAQ: ABVX) with a Market Outperform and raises the price target ...

Core News & Articles

Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United ...

 morgan-stanley-maintains-overweight-on-abivax-raises-price-target-to-101

Morgan Stanley analyst Judah Frommer maintains Abivax (NASDAQ:ABVX) with a Overweight and raises the price target from $71 t...

 btig-reiterates-buy-on-abivax-maintains-112-price-target

BTIG analyst Julian Harrison reiterates Abivax (NASDAQ:ABVX) with a Buy and maintains $112 price target.

 earnings-outlook-for-abivax
Earnings Outlook For Abivax
08/08/2025 15:01:14

 piper-sandler-maintains-overweight-on-abivax-raises-price-target-to-112

Piper Sandler analyst Allison Bratzel maintains Abivax (NASDAQ:ABVX) with a Overweight and raises the price target from $70 ...

 abivax-offering-closes-at-7475m-as-underwriters-take-full-option-net-proceeds-estimated-at-7003m-to-support-inflammation-drug-pipeline

Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION